{"id":70020,"date":"2026-07-15T12:28:14","date_gmt":"2026-07-15T04:28:14","guid":{"rendered":"https:\/\/flcube.com\/?p=70020"},"modified":"2026-07-15T12:28:15","modified_gmt":"2026-07-15T04:28:15","slug":"innovent-biologics-secures-macau-approval-for-dual-immunotherapy-neoadjuvant-regimen-in-msi-h-dmmr-colon-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70020","title":{"rendered":"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\/dMMR Colon Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Innovent Biologics (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>)<\/strong> announced that its <strong>independently developed Daboxin (ipilimumab N01)<\/strong> has received <strong>marketing approval<\/strong> from the <strong>drug regulatory authority of the Macau Special Administrative Region of China<\/strong> for use in combination with <strong>Tyvyt (sintilimab)<\/strong> as a <strong>neoadjuvant therapy<\/strong> for patients with <strong>resectable stage IIB\u2013III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>Macau SAR Drug Regulatory Authority<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing approval<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>Daboxin (ipilimumab N01) + Tyvyt (sintilimab)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neoadjuvant therapy for resectable stage IIB\u2013III MSI-H\/dMMR colon cancer<\/td><\/tr><tr><td><strong>Treatment Setting<\/strong><\/td><td>Pre-surgical (neoadjuvant)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>15 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-development-partnership\" class=\"wp-block-heading\">Drug Profile &amp; Development Partnership<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Daboxin (ipilimumab N01):<\/strong> Recombinant fully human anti-CTLA-4 monoclonal antibody independently developed by Innovent Biologics<\/li>\n\n\n\n<li><strong>Tyvyt (sintilimab):<\/strong> PD-1 inhibitor co-developed by Innovent Biologics and Eli Lilly<\/li>\n\n\n\n<li><strong>Regimen:<\/strong> &#8220;Dual-immunotherapy&#8221; combining CTLA-4 and PD-1 inhibition<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Fully owned by Innovent Biologics (ipilimumab N01) with co-development rights (sintilimab)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-neoshot-iii-phase-3-trial\" class=\"wp-block-heading\">Clinical Evidence \u2013 NeoShot-III Phase 3 Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Dual-Immunotherapy Group<\/th><th>Upfront Surgery Group<\/th><th>Clinical Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Pathological Complete Response (pCR)<\/strong><\/td><td>82% (41\/50 patients)<\/td><td>Not applicable<\/td><td>Exceptional tumor eradication pre-surgery<\/td><\/tr><tr><td><strong>Postoperative Adjuvant Chemotherapy<\/strong><\/td><td>1.6% (1\/62 patients)<\/td><td>21.3% (13\/61 patients)<\/td><td>92% reduction in need for additional chemotherapy<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable, no significant additional safety risks<\/td><td>Standard surgical outcomes<\/td><td>Comparable safety to upfront surgery approach<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The NeoShot-III study demonstrated that neoadjuvant dual-immunotherapy not only achieved remarkable pathological complete response rates but also dramatically reduced the need for postoperative adjuvant chemotherapy, representing a paradigm shift in colon cancer treatment.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-therapeutic-innovation\" class=\"wp-block-heading\">Market Impact &amp; Therapeutic Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MSI-H\/dMMR Colon Cancer:<\/strong> Represents approximately 15% of all colon cancer cases with high unmet need for effective neoadjuvant approaches<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> First approved dual-immunotherapy neoadjuvant regimen specifically for MSI-H\/dMMR colon cancer in Greater China region<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> Establishes Innovent Biologics as a leader in immuno-oncology combinations with potential for global expansion beyond Macau approval<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the commercial launch and market adoption of the dual-immunotherapy regimen. Actual results may differ due to risks including market penetration, competitive dynamics, and potential regulatory expansions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70021,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[29,910,198,15],"class_list":["post-70020","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-combination-therapy","tag-hkg-1801","tag-innovent-biologics","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\/dMMR Colon Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing approval from the drug regulatory authority of the Macau Special Administrative Region of China for use in combination with Tyvyt (sintilimab) as a neoadjuvant therapy for patients with resectable stage IIB\u2013III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70020\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\/dMMR Colon Cancer\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing approval from the drug regulatory authority of the Macau Special Administrative Region of China for use in combination with Tyvyt (sintilimab) as a neoadjuvant therapy for patients with resectable stage IIB\u2013III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70020\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T04:28:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-15T04:28:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\\\/dMMR Colon Cancer\",\"datePublished\":\"2026-07-15T04:28:14+00:00\",\"dateModified\":\"2026-07-15T04:28:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020\"},\"wordCount\":343,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1502.webp\",\"keywords\":[\"Combination therapy\",\"HKG: 1801\",\"Innovent Biologics\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70020#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70020\",\"name\":\"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\\\/dMMR Colon Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1502.webp\",\"datePublished\":\"2026-07-15T04:28:14+00:00\",\"dateModified\":\"2026-07-15T04:28:15+00:00\",\"description\":\"Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing approval from the drug regulatory authority of the Macau Special Administrative Region of China for use in combination with Tyvyt (sintilimab) as a neoadjuvant therapy for patients with resectable stage IIB\u2013III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70020\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/1502.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\\\/dMMR Colon Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70020#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\\\/dMMR Colon Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\/dMMR Colon Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing approval from the drug regulatory authority of the Macau Special Administrative Region of China for use in combination with Tyvyt (sintilimab) as a neoadjuvant therapy for patients with resectable stage IIB\u2013III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70020","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\/dMMR Colon Cancer","og_description":"Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing approval from the drug regulatory authority of the Macau Special Administrative Region of China for use in combination with Tyvyt (sintilimab) as a neoadjuvant therapy for patients with resectable stage IIB\u2013III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.","og_url":"https:\/\/flcube.com\/?p=70020","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-15T04:28:14+00:00","article_modified_time":"2026-07-15T04:28:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70020#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70020"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\/dMMR Colon Cancer","datePublished":"2026-07-15T04:28:14+00:00","dateModified":"2026-07-15T04:28:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70020"},"wordCount":343,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70020#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1502.webp","keywords":["Combination therapy","HKG: 1801","Innovent Biologics","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70020#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70020","url":"https:\/\/flcube.com\/?p=70020","name":"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\/dMMR Colon Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70020#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70020#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1502.webp","datePublished":"2026-07-15T04:28:14+00:00","dateModified":"2026-07-15T04:28:15+00:00","description":"Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing approval from the drug regulatory authority of the Macau Special Administrative Region of China for use in combination with Tyvyt (sintilimab) as a neoadjuvant therapy for patients with resectable stage IIB\u2013III microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70020#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70020"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70020#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1502.webp","width":1080,"height":608,"caption":"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\/dMMR Colon Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70020#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H\/dMMR Colon Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/1502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70020"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70020\/revisions"}],"predecessor-version":[{"id":70022,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70020\/revisions\/70022"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70021"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}